Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review

“…For example, the availability of DMTs given by intravenous infusion in the hospital over recent years has resulted in increased resource use associated with treatment administration and monitoring. A simulation model assessing the efficiency of cladribine tablets or DMTs delivered by infusion from a facility perspective in the UK found that cladribine tablets could decrease the burden of hospital-based administration and monitoring [ 78 ]. However, the cost of DMTs is an important driver in many cost-assessment models, and cladribine tablets has been found to be cost effective compared to alternative treatments in modeling based on use in many country-specific settings, including Finland [ 79 ], Portugal [ 80 ], Spain [ 81 ], Saudi Arabia [ 82 ], Chile [ 83 ], Iran [ 84 ], and Poland [ 85 ].…”